Literature DB >> 17426094

Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer.

Guido C Hovens1, Marcel P Stokkel, Job Kievit, Eleonora P Corssmit, Alberto M Pereira, Johannes A Romijn, Johannes W A Smit.   

Abstract

OBJECTIVE: The relation between serum TSH levels and risk for recurrence or thyroid carcinoma-related death in patients with differentiated thyroid carcinoma has only been studied to a limited extent.
DESIGN: We conducted a single-center observational study in 366 consecutive patients with differentiated thyroid carcinoma, who had all been treated according to the same protocol for initial therapy and follow-up. Median duration of follow-up was 8.85 yr.
METHODS: The relation between summarizing variables of unstimulated serum TSH concentrations (25th, 50th, and 75th percentiles, the percentage of suppressed and unsuppressed TSH values) and risk for recurrence or thyroid carcinoma-related death was analyzed by Cox survival analyses in patients with at least four TSH measurements.
RESULTS: In Cox regression analysis, we found a positive association between serum TSH concentrations and risk for thyroid carcinoma-related death and relapse, even in initially cured patients. The median of the individual TSH concentrations was the best indicator for thyroid carcinoma-related death (hazard ratio 2.03; confidence interval 1.22-3.37) and relapse (hazard ratio 1.41; confidence interval 1.03-1.95). A threshold of 2 mU/liter differentiated best between relapse-free survival and thyroid carcinoma-related death or relapse.
CONCLUSION: Our study supports current guidelines, which advise to aim at TSH levels in the low normal range in cured low-risk patients, whereas TSH levels should be suppressed in noncured or high-risk patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17426094     DOI: 10.1210/jc.2006-2566

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  34 in total

Review 1.  Controversies in the Management of Low-Risk Differentiated Thyroid Cancer.

Authors:  Megan R Haymart; Nazanene H Esfandiari; Michael T Stang; Julia Ann Sosa
Journal:  Endocr Rev       Date:  2017-08-01       Impact factor: 19.871

Review 2.  Managing newly diagnosed thyroid cancer.

Authors:  Anna M Sawka; James D Brierley; Shereen Ezzat; David P Goldstein
Journal:  CMAJ       Date:  2013-10-07       Impact factor: 8.262

Review 3.  Thyroid hormone therapy in differentiated thyroid cancer.

Authors:  Giorgio Grani; Valeria Ramundo; Antonella Verrienti; Marialuisa Sponziello; Cosimo Durante
Journal:  Endocrine       Date:  2019-10-15       Impact factor: 3.633

4.  Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012.

Authors:  Aubrey A Carhill; Danielle R Litofsky; Douglas S Ross; Jacqueline Jonklaas; David S Cooper; James D Brierley; Paul W Ladenson; Kenneth B Ain; Henry G Fein; Bryan R Haugen; James Magner; Monica C Skarulis; David L Steward; Mingxhao Xing; Harry R Maxon; Steven I Sherman
Journal:  J Clin Endocrinol Metab       Date:  2015-07-14       Impact factor: 5.958

5.  One should not just read what one believes: the nearly irresolvable issue of producing truly objective, evidence-based guidelines for the management of differentiated thyroid cancer.

Authors:  Markus Dietlein; F A Verburg; M Luster; C Reiners; F Pitoia; H Schicha
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-05       Impact factor: 9.236

Review 6.  Differentiated thyroid cancer-personalized therapies to prevent overtreatment.

Authors:  Markus Luster; Theresia Weber; Frederik A Verburg
Journal:  Nat Rev Endocrinol       Date:  2014-07-01       Impact factor: 43.330

7.  High Serum Thyrotropin Concentrations within the Reference Range: A Predictor of Malignancy in Nodular Thyroid Disease.

Authors:  Karla Duccini; Marcus Vinicius Leitão de Souza; Ricardo Delfim; Ana Paula Aguiar; Patricia Teixeira; Mario Vaisman
Journal:  Med Princ Pract       Date:  2018-03-07       Impact factor: 1.927

Review 8.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

Review 9.  New insights in risk stratification of differentiated thyroid cancer.

Authors:  Maria Papaleontiou; Megan R Haymart
Journal:  Curr Opin Oncol       Date:  2014-01       Impact factor: 3.645

10.  Endogenous thyrotropin and triiodothyronine concentrations in individuals with thyroid cancer.

Authors:  Jacqueline Jonklaas; Hala Nsouli-Maktabi; Steven J Soldin
Journal:  Thyroid       Date:  2008-09       Impact factor: 6.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.